Contact information
melanie.greenland@paediatrics.ox.ac.uk
https://orcid.org/0000-0001-9363-8844
Oxford Vaccine Group, CCVTM, Churchill Rd, Headington, Oxford, OX3 7LE
Colleges
Research groups
Melanie Greenland
MSc BSc
Senior Medical Statistician & DPhil Student
Melanie is a Senior Medical Statistician and joined the Oxford Vaccine Group in 2020. She has experience of vaccine clinical trials in COVID-19, typhoid fever and pregnancy vaccine trials. She also has experience in women's reproductive health, obstetrics, neonatal, and cardiovascular research in clinical trials, linked electronic health data and Biobank data.
She was awarded a NIHR Doctoral Fellowship for her DPhil research into associations between reactogenicity following vaccination, immune responses and genetics.
Key publications
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
Recent publications
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.
Journal article
Brugha R. et al, (2026), J Pediatr, 289
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Journal article
Kelly E. et al, (2026), J Infect, 92

